lactam bridge comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
The two components of the proton-motive force are thermodynamically equivalent: In mitochondria, the largest part of energy is provided by the potential; in alkaliphile bacteria the electrical energy even has to compensate for a counteracting inverse pH difference. Inversely, chloroplasts operate mainly on ΔpH. However, they also require a small membrane potential for the kinetics of ATP synthesis. In the case of the fusobacterium Propionigenium modestum it drives the counter-rotation of subunits a and c of the FO motor of ATP synthase. The amount of energy released by oxidative phosphorylation is high, compared with the amount produced by fermentation. Glycolysis produces only 2 ATP molecules, but somewhere between 30 and 36 ATPs are produced by the oxidative phosphorylation of the 10 NADH and 2 succinate molecules made by converting one molecule of glucose to carbon dioxide and water, while each cycle of beta oxidation of a fatty acid yields about 14 ATPs. These ATP yields are theoretical maximum values; in practice, some protons leak across the membrane, lowering the yield of ATP.
denotes the Kronecker delta. The physical interpretation of the various terms in the above master equation is straight forward: the terms on the first line describe the growth of fibrils via monomer addition with rate constant
==== Respiratory system ==== The respiratory system allows for gas exchange, particularly of carbon dioxide and oxygen, in human beings. In the process of breathing or ventilation, the muscles of respiration pump air into the lungs, bringing it into close contact with the blood via millions of microscopic air sacs known as alveoli. The upper respiratory tract includes the nose, nasal cavities, sinuses, pharynx and the part of the larynx above the vocal folds; the lower tract includes the lower part of the larynx and the following aiways: the trachea, bronchi, bronchioles and alveoli. The lungs are surrounded by flattened closed sacs known as pleura.
MDMA is being investigated as a potential treatment for social impairments in autism. The British critical psychiatrist Joanna Moncrieff has critiqued the use and study of MDMA and related drugs like psychedelics for treatment of psychiatric disorders, highlighting concerns including excessive hype around these drugs, blurred lines between medical and recreational use, flawed clinical trial findings, financial conflicts of interest, strong expectancy effects and large placebo responses, short-term benefits over placebo, and their potential for adverse effects, among others.
In various species, males provide parental care and females mate with multiple males. For example, recent studies show that extra-pair copulation frequently occurs in monogamous birds in which a "social" father provides intensive care for its "social" offspring. Furthermore, it was observed that newly formed pair bonds in biparental plovers were comparatively weaker than those in uniparental plovers.
Sources: en.wikipedia.org
==== Hydrophobic interaction chromatography ==== Despite the capability of the cation exchange chromatography in purification process, hydrophobic interaction chromatography is also employed, usually at the second step as a polishing step. By using relatively small bead-sized cation resin, the cation exchange chromatography can identify and separate between isoforms by the apparent charges in the condition, but hydrophobic interaction chromatography is capable of identification and separation of the isoforms by their hydrophobicity.
== Background == Cereal grains, namely porridge (and especially oatmeal), became an important breakfast component in North America. Barley was a commonly used grain, though other grains and yellow peas could be used. In many modern cultures, porridge is still eaten as a breakfast dish.
A study by Columbia University researchers suggests hypermetabolism in cells due to impaired mitochondria is a driver of aging. A previously unknown cell mechanism involved in aging is discovered, which explains how cells 'remember' their identity when they divide – the cells' so-called epigenetic memory. A team of scientists from New York University identifies a potential cause of greying hair with age as the failure of melanocyte stem cells to mature with age. The study was carried out using mice, which have identical cells for their fur. According to the research team, the results could provide a basis for reversing the hair greying process. A study affirms and explains why a moderate decrease in body temperature extends lifespan. A study finds that human organs may age at different rates in some individuals, finding that nearly 20% of the 5,676 adults screened showed signs of accelerated aging in one organ and that 1.7% had more than one organ in a state of accelerated aging. By publishing virome-related results, researchers close a major gap in the acceleratingly accumulating research into centenarians' microbiome characteristics for life extension. Scientists at the University of Colorado report what they believe to be the primary mechanism behind cognitive decline in aging, the mis-regulation of the brain protein CaMKII. Three studies indicate platelets, including or especially FF4, are exerkines with health- and life-extension-potential that rejuvenate aging brains of mice.
=== In traditional societies === Fragments of Nolina species have been recovered from various archaeological sites, though their remains haven't been identified to species level. For example, basketry fragments from caves in western Texas, as well as Nolina remains from various other archaeological sites throughout the greater part of the dry Southwestern United States, have been found. Nolina lindheimeriana contains rotenone, which in many societies has been used as fish poison when fishing for food, and as an insecticide. However, it's been documented that Nolina microcara flowering stalks were cooked on open coals for half an hour, peeled and eaten by the Western Apache people. It's known that rotenone is degraded by high heat.
==== Public relations ==== On 26 September 2008, in order to quell the disquiet over the speech by Zhu Yonglan of the CGOSFSC regarding leaders' insulation from the food-security issues faced by the general population, Xinhua issued a brief statement, in Chinese, denying the existence of the centre, the award, or any person named Zhu Yonglan, saying these were "purely rumours". On 16 September, the AQSIQ tests on baby milk powder produced by 109 companies showed 69 batches from 22 companies to be melamine-contaminated; the State Council attempted to reassure that formula produced by most companies in China was safe. It said: "the number of companies with melamine-tainted milk accounted for 20.18% of the total of powdered milk companies in China; the number of tainted batches accounted for 14.05% of the total batches tested." On 30 September, the AQSIQ said its tests on 265 batches from 154 companies showed that "only 18%" had tested positive for melamine: "of the 290 dairies nationwide 154 dairies, representing 87% market share, 134 of these dairies had tested negative for melamine." On 16 September, the AQSIQ published results of tests on 408 liquid milk producers, and found "most dairy products were safe to drink", although the test results showed nearly 10 percent of batches from Mengniu, Yili and Bright were contaminated.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.